Literature DB >> 15972646

ICOS contributes to T cell expansion in CTLA-4 deficient mice.

Miranda E A T van Berkel1, Elise H R Schrijver, Frans M A Hofhuis, Arlene H Sharpe, Anthony J Coyle, Chris P Broeren, Kiki Tesselaar, Mariëtte A Oosterwegel.   

Abstract

Both CD28 and ICOS are important costimulatory molecules that promote Ag-specific cellular and humoral immune reactions. Whereas CD28 is generally thought to be the most important molecule in the initiation of a T cell response, ICOS is considered to act during the effector phase. We have investigated the contribution of ICOS to T cell responses in the absence of CTLA-4-mediated inhibition. Mice lacking CTLA-4, which show spontaneous CD28-mediated CD4(+) T cell activation, expansion and differentiation, were treated with antagonistic alphaICOS antibodies. Blocking the interaction between ICOS and its ligand B7RP-1 significantly reduced this aberrant T cell activation and caused a reduction in T cell numbers. In vitro analysis of CD4(+) T cells from treated mice revealed that ICOS blockade significantly reduced Th1 differentiation, while Th2 differentiation was only moderately inhibited. Further in vitro stimulation experiments demonstrated that ICOS is able to induce proliferation of murine CD4(+) and CD8(+) T cells but only in the presence of IL-2. These results indicate that ICOS is not only important for T cell effector function but also contributes to the expansion phase of a T cell response in the presence of CD28 signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972646     DOI: 10.4049/jimmunol.175.1.182

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Further study of anti-ICOS immunotherapy for rat cardiac allograft rejection.

Authors:  Xuan-Chao Pan; Lei Guo; Ying-Bing Deng; Katsutoshi Naruse; Hiromitsu Kimura; Yasuhiko Sugawara; Masatoshi Makuuchi
Journal:  Surg Today       Date:  2008-08-28       Impact factor: 2.549

2.  Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States.

Authors:  Spencer C Wei; Roshan Sharma; Nana-Ama A S Anang; Jacob H Levine; Yang Zhao; James J Mancuso; Manu Setty; Padmanee Sharma; Jing Wang; Dana Pe'er; James P Allison
Journal:  Immunity       Date:  2019-03-26       Impact factor: 31.745

3.  B7RP-1-ICOS interactions are required for optimal infection-induced expansion of CD4+ Th1 and Th2 responses.

Authors:  Emma H Wilson; Colby Zaph; Markus Mohrs; Andy Welcher; Jerry Siu; David Artis; Christopher A Hunter
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

4.  Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol.

Authors:  Haitian Lu; Barbara L F Kaplan; Thitirat Ngaotepprutaram; Norbert E Kaminski
Journal:  J Leukoc Biol       Date:  2008-11-06       Impact factor: 4.962

5.  ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival.

Authors:  Omid Akbari; Philippe Stock; Everett H Meyer; Gordon J Freeman; Arlene H Sharpe; Dale T Umetsu; Rosemarie H DeKruyff
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

6.  Pilot Study of Delayed ICOS/ICOS-L Blockade With αCD40 to Modulate Pathogenic Alloimmunity in a Primate Cardiac Allograft Model.

Authors:  Natalie A O'Neill; Tianshu Zhang; Gheorghe Braileanu; Xiangfei Cheng; Alena Hershfeld; Wenji Sun; Keith A Reimann; Sia Dahi; Natalia Kubicki; Wessam Hassanein; Christopher Laird; Arielle Cimeno; Agnes M Azimzadeh; Richard N Pierson
Journal:  Transplant Direct       Date:  2018-02-02

7.  BTLA, a key regulator of Vγ9Vδ2 T-cell proliferation.

Authors:  Julie Gertner-Dardenne; Cyril Fauriat; Daniel Olive
Journal:  Oncoimmunology       Date:  2013-07-29       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.